These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 32669405)

  • 21. Correction to: Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Circulation; 2019 Jun; 139(25):e1187. PubMed ID: 31206332
    [No Abstract]   [Full Text] [Related]  

  • 22. Correction to: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Circulation; 2019 Jun; 139(25):e1178-e1181. PubMed ID: 31206328
    [No Abstract]   [Full Text] [Related]  

  • 23. Correction to: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Circulation; 2023 Aug; 148(7):e5. PubMed ID: 37579012
    [No Abstract]   [Full Text] [Related]  

  • 24. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
    Orringer CE; Jacobson TA; Maki KC
    J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pharmacist understanding of the 2013 American College of Cardiology/American Heart Association cholesterol guideline.
    Bucheit JD; Helsing H; Nadpara P; Virani SS; Dixon DL
    J Clin Lipidol; 2018; 12(2):367-374.e3. PubMed ID: 29277495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does clinician-reported lipid guideline adoption translate to guideline-adherent care? An evaluation of the Patient and Provider Assessment of Lipid Management (PALM) registry.
    Lowenstern A; Li S; Navar AM; Virani S; Lee LV; Louie MJ; Peterson ED; Wang TY
    Am Heart J; 2018 Jun; 200():118-124. PubMed ID: 29898839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. American College of Cardiology/American Heart Association (ACC/AHA) Class I Guidelines for the Treatment of Cholesterol to Reduce Atherosclerotic Cardiovascular Risk: Implications for US Hispanics/Latinos Based on Findings From the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).
    Qureshi WT; Kaplan RC; Swett K; Burke G; Daviglus M; Jung M; Talavera GA; Chirinos DA; Reina SA; Davis S; Rodriguez CJ
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28495699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012.
    Wong ND; Young D; Zhao Y; Nguyen H; Caballes J; Khan I; Sanchez RJ
    J Clin Lipidol; 2016; 10(5):1109-18. PubMed ID: 27678427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of 2013 ACC/AHA Blood Cholesterol Guidelines on Statin Treatment Patterns and Low-Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Patients.
    Okerson T; Patel J; DiMario S; Burton T; Seare J; Harrison DJ
    J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28314797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can the ESC/EAS LDL-cholesterol target in patients with diabetes and high cardiovascular risk be achieved in clinical practice? Results from an ambulatory multidisciplinary diabetes center cohort.
    Vidal-Trécan T; Laloi-Michelin M; Bouché C; Juddoo V; Dillinger JG; Azancot I; Kevorkian JP; Salle L; Feron F; Henry P; Gautier JF; Riveline J
    Diabetes Metab; 2019 Dec; 45(6):592-595. PubMed ID: 29609948
    [No Abstract]   [Full Text] [Related]  

  • 31. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
    Wójcik C
    Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implications of the new American College of Cardiology/American Heart Association cholesterol guidelines for primary atherosclerotic cardiovascular disease event prevention in a multi ethnic cohort: Multi-Ethnic Study of Atherosclerosis (MESA).
    Yeboah J; Sillau S; Delaney JC; Blaha MJ; Michos ED; Young R; Qureshi WT; McClelland R; Burke GL; Psaty BM; Herrington DM
    Am Heart J; 2015 Mar; 169(3):387-395.e3. PubMed ID: 25728729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011.
    Ray KK; Kastelein JJ; Boekholdt SM; Nicholls SJ; Khaw KT; Ballantyne CM; Catapano AL; Reiner Ž; Lüscher TF
    Eur Heart J; 2014 Apr; 35(15):960-8. PubMed ID: 24639424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
    Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
    Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.
    Yeboah J; Polonsky TS; Young R; McClelland RL; Delaney JC; Dawood F; Blaha MJ; Miedema MD; Sibley CT; Carr JJ; Burke GL; Goff DC; Psaty BM; Greenland P; Herrington DM
    Circulation; 2015 Sep; 132(10):916-22. PubMed ID: 26224808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What's next for dyslipidemia management? The 2013 ACC/AHA Guidelines, the NLA recommendations, and beyond.
    Waite LH; Phan YL; Spinler SA
    J Am Pharm Assoc (2003); 2016; 56(3):284-92. PubMed ID: 27156942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New American College of Cardiology and American Heart Association cholesterol treatment guidelines: subjects with Type 2 diabetes are under treated with high-intensity statins.
    Tripolt NJ; Sourij H
    Diabet Med; 2014 Jul; 31(7):879-80. PubMed ID: 24612178
    [No Abstract]   [Full Text] [Related]  

  • 38. New Studies Do Not Challenge the American College of Cardiology/American Heart Association Lipid Guidelines.
    Hofer TP; Sussman JB; Hayward RA
    Ann Intern Med; 2016 May; 164(10):683-4. PubMed ID: 26857151
    [No Abstract]   [Full Text] [Related]  

  • 39. A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease.
    Karmali KN; Goff DC; Ning H; Lloyd-Jones DM
    J Am Coll Cardiol; 2014 Sep; 64(10):959-68. PubMed ID: 25190228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide.
    Pokharel Y; Tang F; Jones PG; Nambi V; Bittner VA; Hira RS; Nasir K; Chan PS; Maddox TM; Oetgen WJ; Heidenreich PA; Borden WB; Spertus JA; Petersen LA; Ballantyne CM; Virani SS
    JAMA Cardiol; 2017 Apr; 2(4):361-369. PubMed ID: 28249067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.